Skip to main content


4-Antibody AG and Evotec AG form Strategic Collaboration

By 4-Antibody, Press Release
Press Release.


4-Antibody AG
Hochbergerstrasse 60C
CH-4057 Basel, Switzerland
Phone: +41-61-633-2260

Basel, Switzerland, & Hamburg, Germany, 9th May, 2012

4-Antibody AG and Evotec AG Form Strategic Collaboration

4-Antibody and Evotec launch a new high-content screening platform for early antibody functionality testing

Basel, Switzerland, & Hamburg, Germany, 9th May, 2012: 4-Antibody AG and Evotec AG (Frankfurt
Stock Exchange: EVT, TecDAX) today announced the signing of a strategic collaboration agreement
under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high throughput antibody selection approach will now allow screening of large and diverse antibody populations for desired functionality and activity at a much earlier stage of selection. This unique combined approach is expected to substantially reduce attrition rates at later development stages and is also expected to be particularly beneficial in aiding earlier distinction and selection between antagonist and agonist antibodies.

Evotec’s fully integrated drug discovery and development infrastructure has been adapted to facilitate screening of human antibody populations in combination with high throughput/high content screening coupled to specific biological assays. The new collaboration integrates the output from 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid discovery of fully human antibodies into Evotec’s high throughput cell-based assay platform.

The Retrocyte Display® technology (Retroviral B lymphocyte Display) is a high throughput cellular antibody expression platform which allows expression and screening of full-length immunoglobulin antibody libraries in mammalian B-lineage cells for the identification of antigen-specific fully human monoclonal antibodies. B-lineage cells are designed by nature for optimal antibody display and are capable of generating ‘better-behaved’, fully human antibodies.

Dr Robert Burns, 4-Antibody’s CEO, said:

“We’re delighted to announce this collaboration with Evotec which will allow pharma players who elect to fully out-source antibody drug discovery access to our platform. This is an ideal partnership since it gives 4-Antibody access to a broader market beyond its primary targets – the companies we think of as ‘technology internalizers’. These companies license our cellular antibody libraries to allow them to screen large number of targets through our technology platform in their own in-house research labs. So, our primary business model remains unchanged but with the Evotec collaboration we can now offer a fully integrated discovery-to-development model in the antibody drug space for pharma players who are looking for complete out-sourcing. Everyone in the drug discovery space understands the desirability of introducing functional testing as early as possible in the selection of drug candidates; and I don’t see other service players who can offer this fully integrated discovery to development capability in the antibody drug space.”

Dr Werner Lanthaler, CEO at Evotec added:

“We are excited to launch our high-content screening capabilities for antibody selection in conjunction with 4-Antibody, one of the technological leaders in the antibody field. Through a combination of our capabilities, we target an approach to select for functional antibodies. This “EVOmAb” turn-key solution will deliver to our customers a much higher chance to bring an antibody to the market than traditional affinity-selected antibody approaches”

Both parties agreed to share financial rewards of this approach. Evotec will initially pay a €2m access fee to 4-Antibody, which will be fully reimbursed from future returns. Going forward the Parties will share profits.
About 4-Antibody AG

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The company’s proprietary discovery engine is the in vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an in-house pipeline of antibody drugs. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland and Jena, Germany. For more information please visit:

About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer’s disease. For additional information please go to


Further Information:

Dr Robert Burns
4-Antibody AG
t: +41-61-633-22-60

Dr Werner Lanthaler
Evotec AG
t: + 49.40.56081.242

Dr Robert Mayer
Account Manager
College Hill
t: +49-89-5238-8030

4-Antibody announces long-term collaboration with Boehringer Ingelheim with a maximum value of EUR 177.5m (CHF 266m) for 4-Antibody

By 4-Antibody, Press Release
Press Release.


Basel, Switzerland: 4-Antibody AG today announced a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications.

4-Antibody will use its proprietary and unencumbered Hu-PAC™ and Retrocyte Display™ technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones.


About 4-Antibody AG

4-Antibody AG is a privately held Swiss Biotech company active in the area of therapeutic antibody drug development. 4-Antibody AG has developed a portfolio of powerful, proprietary antibody discovery and engineering platforms, including the Hu-PAC® and the Retrocyte Display® technologies. 4-Antibody AG owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen of granted patents worldwide. The company has 40 employees working at its headquarter in Basel, Switzerland, and its subsidiary in Jena, Germany.